Mozambique

Activities  2015 International Activity Report

In Mozambique, MSF continues to work with the Ministry of Health to develop innovative strategies to combat HIV/AIDS and tuberculosis (TB), and to respond to emergencies such as cholera epidemics.

Despite adopting an ambitious acceleration plan to tackle HIV/AIDS in 2013, Mozambique is still struggling to deal with the epidemic; 11.5 per cent of adults living in the country have HIV, and worryingly, the number continues to grow, in part because of structural problems such as shortages of health staff and a recurrent lack of essential medicines. MSF is providing a wide range of services, from specialised medical care for patients with advanced stages of AIDS to supporting strategies that enable stable, healthy HIV patients to access their medicines more easily.

In the capital Maputo, MSF focuses on HIV/AIDS patients who need specialised care, including those who have failed first-line antiretroviral treatment or are suffering from co-infections such as multidrug-resistant TB (MDR-TB) and viral hepatitis, or cancers like Kaposi’s sarcoma or those caused by human papillomavirus. Comprehensive care is also provided to MDR-TB patients and HIV-infected women and children. In 2015, MSF provided viral load monitoring to 28,394 patients.

MSF scaled up its activities in the ‘corridor project’ that was started in 2014 along the commercial route linking the busy Beira harbour to the mining area of Tete province. This year, it provided testing for HIV and sexually transmitted infections to 967 long-distance truck drivers and 548 sex workers, a particularly vulnerable group with an HIV prevalence of 55 per cent.

Cholera is endemic in Mozambique, and there were several exceptionally large and unrelated outbreaks in the centre and north of the country in 2015. MSF teams in Tete and Zambezia provinces treated a total of 416 patients.

Year MSF first worked in the country: 1984.

2015 Key figures
Patients on first-line ARV treatment 34,300
Patients treated for cholera 4,700
Patients on second-line ARV treatment 1,000
Patients under treatment for TB 800
          of which for MDR-TB 100
No. staff in 2015 382
2015 Expenditure €10.0 million

Figures from 2015 International Activity Report
and 2015 International Financial Report

 

Sort by: